ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2024
Hepatitis C Screening in Community Pharmacies-A Feasibility and Knowledge Transfer Study: PHARMA-C.
Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.The Lancet regional health. Europe · 2026Review
- Experiences of people who inject drugs with hepatitis C testing and their perceptions of a pharmacy-based testing option: a qualitative study.International journal of clinical pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New strategies are needed to increase access to hepatitis C virus (HCV) testing. This study evaluated the feasibility of HCV rapid testing in community pharmacies in Quebec (Canada) and assessed knowledge transfer (KT). Methods: PHARMA-C was a 6-month (February to September 2022) prospective KT study. Community pharmacists (CPs) were recruited and trained to identify HCV risk factors, conduct rapid antibody tests (OraQuickHCV), and pre- and post-test counselling, and link positive cases to care. Health care users (HUs) were included according to HCV risk factors. An advisory committee and focus groups provided guidance, feedback, and identified barriers and facilitators to improve the program. A pre- and post-intervention questionnaire was completed by CPs to assess feasibility and KT. HUs completed a satisfaction survey. Results: A total of 32 CPs were included and 16 performed 101 HCV tests. Two positive cases were identified and linked to care. Comparison of pre- and post-intervention surveys shows that pharmacists felt more confident in identifying HCV risk factors, communicating information to patients related to HCV, and performing the HCV screening test at the end of the intervention. HCV screening in pharmacies was considered feasible by 77.8% of CPs. The intervention lasted approximately 22 minutes. The main barriers to implementation were lack of time and fear of stigmatizing HUs. Promotional material and training were the main facilitators. Conclusion: HCV point-of-care testing by CPs is feasible in Quebec. Expanding pharmacists' scope of practice to include HCV screening and increasing pharmacists' role in the HCV care cascade is encouraged in order to further efforts toward HCV elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.